Article Page

Abstract

Active immunotherapy is emerging as a potential therapeutic approach for prostate cancer. First phase I trials of an Ii-Key/HER-2/neu(776–790) hybrid peptide vaccine (AE37) with recombinant granulocyte macrophage colony-stimulating factor as adjuvant in patients with HER-2/neu+prostate cancer have shown positive resutls. The primary functionalities of ChemMine Tools fall into five major application areas: data visualization, structure comparisons, similarity searching, compound clustering and prediction of chemical properties. First, users can upload compound data sets to the online Compound Workbench. Numerous utilities are provided for compound viewing, structure drawing and format interconversion. Second, pairwise structural similarities among compounds can be quantified. Third, interfaces to ultra-fast structure similarity search algorithms are available to efficiently mine the chemical space in the public domain. These include fingerprint and embedding/ indexing algorithms. Fourth, the service includes a Clustering Toolbox that integrates cheminformatic algorithms with data mining utilities to enable systematic structure and activity based analyses of custom compound sets. Fifth, physicochemical property descriptors of custom compound sets can be calculated. These descriptors are important for assessing the bioactivity profile of compounds in silico and quantitative structure—activity relationship (QSAR) analyses. ChemMine Tools is available at: http://chemmine.ucr.ed. Richard Feynman once said, “I think it is safe to say that no one understands Quantum Mechanics”. The well-known article on the Einstein-Podolsky-Rosen (EPR) paradox brought forth further doubts on the interpretation of quantum theory. Einstein’s doubt on quantum theory is a double- edged sword: experimental verification of quantum theory would contradict the hypothesis that speed of light is finite. It has been almost a century since the creation of quantum theory and special relativity, and the relevant doubts brought forward remain unresolved. We posit that the existence of discontinuity points and quantum wormholes would imply superluminal phenomenon or infinite speed of light, which provides for an important supplement to the invariance principle of the speed of light and superluminal phenomena. This can potentially resolve the inconsistency between special relativity and quantum theory applied to a Supplement of the Invariance Principle of the Speed of Light and the Quantum Theory on a COMPUTER-assisted Identified Ii-Key/HER-2/ neu(776-790) Hybrid poly-mimic peptide mimotopic vaccine-like chemostructure with active pharmacophore sites as a future in silico promising novel inhibitor trans-activator in Prostate Cancer Patients.

Keywords

Invariance Principle of the Speed of Light, Superluminal Phenomena, Uncertainty Principle, Quantum Nonlocality, Quantum Wormholes, COMPUTER-assisted, Ii-Key/HER-2/ neu(776-790), Hybrid poly-mimic, peptide mimotopic, vaccine-like ,chemostructure, active pharmacophore sites, in silico, novel inhibitor, trans-activator, Prostate Cancer Patients.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) A Supplement to the Invariance Principle of the Speed of Light and the Quantum Theory on a COMPUTER-assisted Identified Ii-Key/HER-2/ neu(776-790) Hybrid poly-mimic peptide mimotopic vaccine-like chemostructure with active pharmacophore sites as a future in silico promising novel inhibitor trans-activator in Prostate Cancer Patients.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available